CollectionsSanofi Pasteur
IN THE NEWS

Sanofi Pasteur

FEATURED ARTICLES
BUSINESS
May 7, 2009 | By Miriam Hill INQUIRER STAFF WRITER
The federal government has given the green light for Sanofi Pasteur Inc. to manufacture flu vaccine at its Poconos site, a boost to the country's ability to cope with future flu outbreaks. The U.S. Food and Drug Administration said it approved the facility, in Swiftwater, Pa., to produce seasonal influenza vaccine. The agency also said the facility could make a vaccine against the new 2009 H1N1 influenza strain. The Centers for Disease Control and Prevention has not yet decided whether to create a vaccine against that strain.
NEWS
July 28, 2008 | ASSOCIATED PRESS
PARIS - Sanofi-Aventis SA said its planned $551 million acquisition of Acambis PLC will bolster its leading position in the vaccine market and strengthen its development pipeline. The deal, expected to close by the end of September, would add Acambis' key smallpox vaccine ACAM2000 to the existing portfolio of Sanofi Pasteur, the vaccines business of Sanofi-Aventis. Sanofi Pasteur has a drug-development center in Malvern and facilities in Swiftwater, Pa., in the Poconos. In April, Acambis won a $425 million, 10-year contract to provide the U.S. government with its ACAM2000 vaccine, which is the mainstay of the U.S. stockpile against smallpox.
NEWS
June 16, 2008 | INQUIRER STAFF
Sanofi Pasteur, of Swiftwater in Northeastern Pennsylvania, said today it would donate 60 million doses of influenza vaccine to the World Health Organization. The vaccine, to be supplied over three years, will help build a stockpile that can be used in poor regions of the world in the event of an outbreak of pandemic influenza. Sanofi-Pasteur is the vaccines division of Sanofi-Aventis Group, the Paris pharmaceutical company. It has U.S. research and development headquarters in Malvern.
NEWS
August 26, 2010
Sanofi Pasteur said the U.S. Food and Drug Administration had accepted its application to extend the age group that can receive a vaccine that can prevent meningococcal disease. Sanofi Pasteur, the vaccines division of French drugmaker Sanofi-Aventis with U.S. headquarters in Swiftwater, Monroe County, said the FDA was reviewing its supplemental biologics license application for Menactra to be used in infants and toddlers. All of the Menactra vaccine is made in Swiftwater, said Sanofi spokeswoman Susan Watkins.
BUSINESS
November 11, 2005 | By Linda Loyd INQUIRER STAFF WRITER
Few small biotechnology companies would call ending a licensing agreement with a major pharmaceutical company a positive development. But Aphton Corp. did just that yesterday, announcing its agreement with Sanofi Pasteur was terminated to allow the smaller company to pursue another partner. Aphton and Sanofi Pasteur dissolved a licensing agreement, signed in 1997, that called for Sanofi Pasteur to copromote Aphton's cancer compound, Insegia. The move allows Aphton to seek a new partner to financially support additional clinical studies of its drug for gastric cancer.
BUSINESS
July 4, 2006 | By Thomas Ginsberg INQUIRER STAFF WRITER
Sanofi Pasteur Inc., the vaccine-maker in northeastern Pennsylvania, has found and destroyed a small amount of contaminated vaccine material at its plant, the company and regulators said yesterday. The contaminated bulk vaccine concentrate was never refined into the actual vaccine, Fluzone, or released to the public, the officials said. The company said the "unusual" contamination was discovered during a routine inspection and was reported in March to the Food and Drug Administration.
BUSINESS
October 24, 2006 | By Thomas Ginsberg INQUIRER STAFF WRITER
Drug-safety officials and the vaccine-maker Sanofi Pasteur are studying reports of a rare paralysis condition among at least 15 young people among millions vaccinated with Menactra, its meningitis vaccine. The cases of Guillain-Barre Syndrome, occurring six weeks after vaccinations, amounted to about 1.25 people out of one million vaccinated nationwide, according to officials at the U.S. Centers for Disease Control and Prevention. An estimated 6.6 million doses of the vaccine, manufactured in Swiftwater, Pa., about 100 miles north of Philadelphia, have been administered since it was introduced in March 2005, the company said.
NEWS
March 13, 2014 | By Stacey Burling, Inquirer Staff Writer
Until now, hospitals have largely dealt with Clostridium difficile , a bacterial infection that bedevils vulnerable patients in health-care settings, by attempting to prevent it with intensive disinfection or treating it with antibiotics. Temple University Hospital is trying something new: a vaccine. Temple is among 200 sites in 17 countries that are testing a new vaccine produced by Sanofi Pasteur in Swiftwater, Pa. The Phase III clinical trial, known as Cdiffense, aims to recruit up to 15,000 adults.
BUSINESS
September 16, 2005 | By Linda Loyd INQUIRER STAFF WRITER
The federal government said yesterday that it had awarded Sanofi Pasteur Inc. a $100 million contract to produce an avian flu vaccine. It also awarded GlaxoSmithKline P.L.C. a $2.8 million contract to supply its antiviral drug Relenza, which can be used to treat influenza. The Department of Health and Human Services said the contracts were part of the government's plan to buy enough vaccine for 20 million people and antivirals to treat 20 million more in the event of an avian flu pandemic.
BUSINESS
April 28, 2009 | By Miriam Hill INQUIRER STAFF WRITER
There is no vaccine against the deadly new strain of swine flu, but the federal government is pondering whether to make one. That's a tricky decision, but if the Centers for Disease Control and Prevention gives the go-ahead, it likely will turn to pharmaceutical companies with operations in this region. In the Poconos, the French vaccine-maker Sanofi Pasteur already has the capacity to churn out 50 million doses of its seasonal influenza vaccine, Fluzone, which protects against a different strain of the flu. Spokeswoman Donna Cary said the company was ready to help the CDC should the agency decide to create and manufacture a vaccine against the swine flu. The company also is close to bringing a new vaccine facility into full production at the Swiftwater, Pa., location that will double its capacity, Cary said.
1 | 2 | 3 | 4 | 5 | Next »
ARTICLES BY DATE
NEWS
September 20, 2014 | By Stacey Burling, Inquirer Staff Writer
It is not yet flu season, but it is now officially flu shot season. Thomas Frieden, director of the Centers for Disease Control and Prevention, rolled up his sleeve at a news conference in Washington on Thursday to emphasize the need for more Americans to protect themselves and the people around them from the common, and potentially deadly, disease. He didn't flinch as the needle pierced his skin. "I hardly felt it," he said cheerfully. While Frieden predicted an ample supply of vaccine for the season, which typically runs from October through March, some local hospitals are reporting delays in shipments.
NEWS
March 13, 2014 | By Stacey Burling, Inquirer Staff Writer
Until now, hospitals have largely dealt with Clostridium difficile , a bacterial infection that bedevils vulnerable patients in health-care settings, by attempting to prevent it with intensive disinfection or treating it with antibiotics. Temple University Hospital is trying something new: a vaccine. Temple is among 200 sites in 17 countries that are testing a new vaccine produced by Sanofi Pasteur in Swiftwater, Pa. The Phase III clinical trial, known as Cdiffense, aims to recruit up to 15,000 adults.
NEWS
January 3, 2013 | By Don Sapatkin, Inquirer Staff Writer
A quadruple-dose flu vaccine for the elderly also provides better protection for people with HIV, researchers reported Tuesday in the first of several studies to publish results of high-dose vaccine for people with compromised immune systems. The team of researchers from Philadelphia institutions will ask a federal advisory committee to recommend high-dose vaccination for HIV-positive people, said Pablo Tebas, an infectious-diseases physician at the Hospital of the University of Pennsylvania and senior author of the paper in Annals of Internal Medicine.
NEWS
August 26, 2010
Sanofi Pasteur said the U.S. Food and Drug Administration had accepted its application to extend the age group that can receive a vaccine that can prevent meningococcal disease. Sanofi Pasteur, the vaccines division of French drugmaker Sanofi-Aventis with U.S. headquarters in Swiftwater, Monroe County, said the FDA was reviewing its supplemental biologics license application for Menactra to be used in infants and toddlers. All of the Menactra vaccine is made in Swiftwater, said Sanofi spokeswoman Susan Watkins.
BUSINESS
November 15, 2009 | By Miriam Hill INQUIRER STAFF WRITER
Of the companies that make the vaccine for the swine flu, only one has avoided the production problems caused by a slow-growing virus strain. AstraZeneca P.L.C.'s MedImmune Inc. is churning out nearly three million doses of its vaccine a week at its facility on Red Lion Road near the Northeast Philadelphia Airport. Production problems at other makers of H1N1 vaccine have proved to be an unintended boon for MedImmune. Other manufacturers, including Novartis AG, Sanofi Pasteur Inc., GlaxoSmithKline P.L.C.
BUSINESS
November 12, 2009 | By Miriam Hill INQUIRER STAFF WRITER
Sanofi-Aventis Group, under pressure with other vaccine-makers to meet intense public demand for flu vaccine in the United States, yesterday said it solved problems that had slowed production and was working around-the-clock to deliver the 75 million doses of H1N1 vaccine it promised the federal government by the end of December. Many employees at the company's Poconos plant here volunteered to work 12-hour shifts seven days a week, some have canceled honeymoons, and one reported to work in the afternoon after his child was born in the morning, company officials said.
BUSINESS
November 11, 2009 | By Miriam Hill INQUIRER STAFF WRITER
GlaxoSmithKline P.L.C. today said the federal Food and Drug Administration approved its H1N1 flu vaccine for use in the United States. The U.S. government has ordered 7.6 million doses of the Glaxo vaccine as part of a total 250 million doses secured from several companies, including Sanofi-Pasteur and AstraZeneca. Glaxo's vaccine will be produced in multi-dose vials from bulk vaccine produced at company operations in Quebec, Canada. The company, which is based in London but has major operations in the Philadelphia region, expects to start shipping the H1N1 vaccine to U.S. locations in December and deliver all 7.6 million doses by the end of the year.
NEWS
August 24, 2009 | By Sally A. Downey INQUIRER STAFF WRITER
G. Willard Webster, 95, a bacteriologist who helped produce lifesaving vaccines, died Aug. 13 at Foulkeways, a Quaker retirement community in Gwynedd. While studying physics at the University of Pennsylvania, Mr. Webster washed glassware in a laboratory at Sharpe & Dohme, now Merck & Co. He eventually became a medical researcher in the pharmaceutical company's laboratory and launched a career. During World War II, he received a deferment from military service to work with scientists, including Jonas Salk, who were preparing and testing an influenza vaccine.
BUSINESS
August 21, 2009 | By Miriam Hill and Don Sapatkin INQUIRER STAFF WRITERS
GlaxoSmithKline P.L.C. has won swift approval from the federal government to produce and sell a booster vaccine against Haemophilus influenzae type b, which should help eliminate shortages of the shot against the deadly disease. The London drugmaker, which has large operations in the Philadelphia region, said late Wednesday that its Hiberix vaccine was approved as a booster dose for children 15 months to 4 years old. The vaccine targets the bacterial infection known as Hib, which can cause meningitis, pneumonia, and other deadly illnesses.
BUSINESS
May 7, 2009 | By Miriam Hill INQUIRER STAFF WRITER
The federal government has given the green light for Sanofi Pasteur Inc. to manufacture flu vaccine at its Poconos site, a boost to the country's ability to cope with future flu outbreaks. The U.S. Food and Drug Administration said it approved the facility, in Swiftwater, Pa., to produce seasonal influenza vaccine. The agency also said the facility could make a vaccine against the new 2009 H1N1 influenza strain. The Centers for Disease Control and Prevention has not yet decided whether to create a vaccine against that strain.
1 | 2 | 3 | Next »
|
|
|
|
|